Incidence, risk factors, and long‐term outcomes associated with antibody‐mediated rejection — The long‐term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study-Reference-Cited by-同舟云学术

Incidence, risk factors, and long‐term outcomes associated with antibody‐mediated rejection — The long‐term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study

Published:2021-05-18 Issue:7 Volume:35 Page:
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Hart Allyson¹²^ORCID,Schladt David P.²,Matas Arthur J.³^ORCID,Itzler Robbin⁴,Israni Ajay K.¹²^ORCID,Kasiske Bertram L.¹²

Affiliation:

1. Department of Medicine Hennepin County Medical CenterHennepin Healthcare Minneapolis MN USA

2. Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA

3. Transplantation Division Department of Surgery University of Minnesota Minneapolis MN USA

4. CSL Behring King of Prussia PA USA

Funder

CSL Behring

Publisher

Wiley

Subject

Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ctr.14337

Reference34 articles.

1. Antibody-Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure

2. Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence

3. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary

4. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience

5. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Rejection After Kidney Transplantation;Transplantation;2024-08-28

2. Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation;Journal of Clinical Medicine;2023-07-26

3. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena;Transplantation;2023-01-26

4. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials;Expert Opinion on Emerging Drugs;2022-04-03

5. Innovative immunosuppression in kidney transplantation: A challenge for unmet needs;World Journal of Transplantation;2022-03-18